The Genetics of the Epilepsies

Current Neurology and Neuroscience Reports

Volumn 15, Issue 7, 2015, Pages

  El Achkar, Christelle M ^a   Olson, Heather E ^a   Poduri, Annapurna ^a   Pearl, Phillip L ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

Channelopathies; Epilepsy; Epilepsy syndrome; Epileptic encephalopathy; Genetics

Indexed keywords

BENIGN CHILDHOOD EPILEPSY; COPY NUMBER VARIATION; CORTICAL DYSPLASIA; DISEASE COURSE; EARLY ONSET EPILEPTIC ENCEPHALOPATHY; EPILEPSY; FEBRILE CONVULSION; FLUORESCENCE IN SITU HYBRIDIZATION; FOCAL EPILEPSY; GENE DUPLICATION; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENERALIZED EPILEPSY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC COUNSELING; GENETIC DISORDER; GENETIC SCREENING; GENOME IMPRINTING; GENOTYPE PHENOTYPE CORRELATION; HUMAN; KARYOTYPING; LANDAU KLEFFNER SYNDROME; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; MYOCLONUS EPILEPSY; NONHUMAN; REVIEW; SUDDEN DEATH; TRINUCLEOTIDE REPEAT; ANIMAL; CHANNELOPATHY; GENETICS; MUTATION;

ANIMALS; CHANNELOPATHIES; EPILEPSY; GENETIC COUNSELING; GENETIC TESTING; HUMANS; MUTATION;

EID: 84930192922     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-015-0559-8     Document Type: Review

References (166)

1. Lee BI, Heo K. Epilepsy: new genes, new technologies, new insights. Lancet Neurol. 2014;13(1):7–9.
2. Hauser WA, Kurland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia. 1975;16(1):1–66.
3. Thomas RH, Berkovic SF. The hidden genetics of epilepsy-a clinically important new paradigm. Nat Rev Neurol. 2014;10(5):283–92.
4. Buiting K. Prader-Willi syndrome and Angelman syndrome. Am J Med Genet C: Semin Med Genet. 2010;154C(3):365–76.
5. Buiting K et al. Inherited microdeletions in the Angelman and Prader-Willi syndromes define an imprinting centre on human chromosome 15. Nat Genet. 1995;9(4):395–400.
6. Evrony GD et al. Cell lineage analysis in human brain using endogenous retroelements. Neuron. 2015;85(1):49–59.
7. Lindhout D. Somatic mosaicism as a basic epileptogenic mechanism? Brain. 2008;131(Pt 4):900–1.
8. Shirley MD et al. Sturge-Weber syndrome and port-wine stains caused by somatic mutation in GNAQ. N Engl J Med. 2013;368(21):1971–9.
9. Poduri A et al. Somatic mutation, genomic variation, and neurological disease. Science. 2013;341(6141):1237758.
10. Riviere JB et al. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet. 2012;44(8):934–40.
11. Mirzaa GM, Poduri A. Megalencephaly and hemimegalencephaly: breakthroughs in molecular etiology. Am J Med Genet C: Semin Med Genet. 2014;166C(2):156–72.
12. Poduri A et al. Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron. 2012;74(1):41–8. This study was one of the earliest to demonstrate the role of somatic mutations limited to the brain and involving the AKT3 gene in the development of hemimgalencephaly.
13. Gennaro E et al. Somatic and germline mosaicisms in severe myoclonic epilepsy of infancy. Biochem Biophys Res Commun. 2006;341(2):489–93.
14. Depienne C et al. Mechanisms for variable expressivity of inherited SCN1A mutations causing Dravet syndrome. J Med Genet. 2010;47(6):404–10.
15. Martin MS et al. The voltage-gated sodium channel Scn8a is a genetic modifier of severe myoclonic epilepsy of infancy. Hum Mol Genet. 2007;16(23):2892–9.
16. Doty CN. SCN9A: another sodium channel excited to play a role in human epilepsies. Clin Genet. 2010;77(4):326–8.
17. Meisler MH, O’Brien JE, Sharkey LM. Sodium channel gene family: epilepsy mutations, gene interactions and modifier effects. J Physiol. 2010;588(Pt 11):1841–8.
18. Singh NA et al. KCNQ2 and KCNQ3 potassium channel genes in benign familial neonatal convulsions: expansion of the functional and mutation spectrum. Brain. 2003;126(Pt 12):2726–37.
19. Kato M et al. Clinical spectrum of early onset epileptic encephalopathies caused by KCNQ2 mutation. Epilepsia. 2013;54(7):1282–7.
20. Scheffer IE et al. X-linked myoclonic epilepsy with spasticity and intellectual disability: mutation in the homeobox gene ARX. Neurology. 2002;59(3):348–56.
21. Depienne C et al. Sporadic infantile epileptic encephalopathy caused by mutations in PCDH19 resembles Dravet syndrome but mainly affects females. PLoS Genet. 2009;5(2), e1000381.
22. Saitsu H et al. De novo mutations in the gene encoding STXBP1 (MUNC18-1) cause early infantile epileptic encephalopathy. Nat Genet. 2008;40(6):782–8.
23. Euro, E.-R.E.S.C., P. Epilepsy Phenome/Genome, Epi KC. De novo mutations in synaptic transmission genes including DNM1 cause epileptic encephalopathies. Am J Hum Genet. 2014;95(4):360–70.
24. Mari F et al. CDKL5 belongs to the same molecular pathway of MeCP2 and it is responsible for the early-onset seizure variant of Rett syndrome. Hum Mol Genet. 2005;14(14):1935–46.
25. Poduri A et al. Homozygous PLCB1 deletion associated with malignant migrating partial seizures in infancy. Epilepsia. 2012;53(8):e146–50.
26. Shen J et al. Mutations in PNKP cause microcephaly, seizures and defects in DNA repair. Nat Genet. 2010;42(3):245–9.
27. Mills PB et al. Epilepsy due to PNPO mutations: genotype, environment and treatment affect presentation and outcome. Brain. 2014;137(Pt 5):1350–60.
28. Pearl PL, Gospe SM. Pyridoxine or pyridoxal-5′-phosphate for neonatal epilepsy: the distinction just got murkier. Neurology. 2014;82(16):1392–4.
29. Poduri A et al. Genetic testing in the epilepsies-developments and dilemmas. Nat Rev Neurol. 2014;10(5):293–9.
30. Goto Y, Nonaka I, Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. 1990;348(6302):651–3.
31. Veeramah KR et al. Exome sequencing reveals new causal mutations in children with epileptic encephalopathies. Epilepsia. 2013;54(7):1270–81.
32. Hortopan GA, Dinday MT, Baraban SC. Zebrafish as a model for studying genetic aspects of epilepsy. Dis Model Mech. 2010;3(3–4):144–8.
33. Olivetti PR, Noebels JL. Interneuron, interrupted: molecular pathogenesis of ARX mutations and X-linked infantile spasms. Curr Opin Neurobiol. 2012;22(5):859–65.
34. Liu Y et al. Dravet syndrome patient-derived neurons suggest a novel epilepsy mechanism. Ann Neurol. 2013;74(1):128–39. Data from this study uncovered a potential mechanism for Dravet syndrome that is cell autonomous, which was not described before. This study highlights the role of patient-specific iPSC-derived neurons in the understanding of pathogenesis of certain epilepsies.
35. Scheffer IE et al. Dravet syndrome or genetic (generalized) epilepsy with febrile seizures plus? Brain Dev. 2009;31(5):394–400.
36. Orhan G et al. Dominant-negative effects of KCNQ2 mutations are associated with epileptic encephalopathy. Ann Neurol. 2014;75(3):382–94.
37. Berg AT et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia. 2010;51(4):676–85.
38. Mastrangelo M, Leuzzi V. Genes of early-onset epileptic encephalopathies: from genotype to phenotype. Pediatr Neurol. 2012;46(1):24–31.
39. Allen AS et al. De novo mutations in epileptic encephalopathies. Nature. 2013;501(7466):217–21. This large scale study confirmed and identified multiple new genes causative of epileptic encephalopathies, via exome sequencing of 264 probands and their parents.
40. Olson HE et al. Genetic mechanisms of ohtahara syndrome, a cohort study. 2014: Annals of neurology. p. S178-S178.
41. Ohtahara S, Yamatogi Y. Ohtahara syndrome: with special reference to its developmental aspects for differentiating from early myoclonic encephalopathy. Epilepsy Res. 2006;70 Suppl 1:S58–67.
42. Saitsu H et al. Whole exome sequencing identifies KCNQ2 mutations in Ohtahara syndrome. Ann Neurol. 2012;72(2):298–300.
43. Nakamura K et al. Clinical spectrum of SCN2A mutations expanding to Ohtahara syndrome. Neurology. 2013;81(11):992–8.
44. Kato M et al. Frameshift mutations of the ARX gene in familial Ohtahara syndrome. Epilepsia. 2010;51(9):1679–84.
45. Molinari F et al. Mutations in the mitochondrial glutamate carrier SLC25A22 in neonatal epileptic encephalopathy with suppression bursts. Clin Genet. 2009;76(2):188–94.
46. Saitsu H et al. Compound heterozygous BRAT1 mutations cause familial Ohtahara syndrome with hypertonia and microcephaly. J Hum Genet. 2014;59(12):687–90.
47. Saitsu H et al. CASK aberrations in male patients with Ohtahara syndrome and cerebellar hypoplasia. Epilepsia. 2012;53(8):1441–9.
48. Kato M et al. PIGA mutations cause early-onset epileptic encephalopathies and distinctive features. Neurology. 2014;82(18):1587–96.
49. Dravet C, Oguni H. Dravet syndrome (severe myoclonic epilepsy in infancy). Handb Clin Neurol. 2013;111:627–33.
50. Patino GA et al. A functional null mutation of SCN1B in a patient with Dravet syndrome. J Neurosci. 2009;29(34):10764–78.
51. Carvill GL et al. GABRA1 and STXBP1: novel genetic causes of Dravet syndrome. Neurology. 2014;82(14):1245–53.
52. Carvill GL et al. Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1. Nat Genet. 2013;45(7):825–30.
53. Nava C et al. De novo mutations in HCN1 cause early infantile epileptic encephalopathy. Nat Genet. 2014;46(6):640–5.
54. Shi X et al. Mutational analysis of GABRG2 in a Japanese cohort with childhood epilepsies. J Hum Genet. 2010;55(6):375–8.
55. Barcia G et al. De novo gain-of-function KCNT1 channel mutations cause malignant migrating partial seizures of infancy. Nat Genet. 2012;44(11):1255–9.
56. Carranza Rojo D et al. De novo SCN1A mutations in migrating partial seizures of infancy. Neurology. 2011;77(4):380–3.
57. Poduri A et al. SLC25A22 is a novel gene for migrating partial seizures in infancy. Ann Neurol. 2013;74(6):873–82.
58. Milh M et al. Novel compound heterozygous mutations in TBC1D24 cause familial malignant migrating partial seizures of infancy. Hum Mutat. 2013;34(6):869–72.
59. Dhamija R et al. Novel de novo SCN2A mutation in a child with migrating focal seizures of infancy. Pediatr Neurol. 2013;49(6):486–8.
60. Zhang X et al. Mutations in QARS, encoding glutaminyl-tRNA synthetase, cause progressive microcephaly, cerebral-cerebellar atrophy, and intractable seizures. Am J Hum Genet. 2014;94(4):547–58.
61. Ohba C et al. Early onset epileptic encephalopathy caused by de novo SCN8A mutations. Epilepsia. 2014;55(7):994–1000.
62. Paciorkowski AR, Thio LL, Dobyns WB. Genetic and biologic classification of infantile spasms. Pediatr Neurol. 2011;45(6):355–67.
63. Mefford HC et al. Rare copy number variants are an important cause of epileptic encephalopathies. Ann Neurol. 2011;70(6):974–85.
64. Consortium EK. Epi4K: gene discovery in 4,000 genomes. Epilepsia. 2012;53(8):1457–67.
65. Chu-Shore CJ et al. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia. 2010;51(7):1236–41.
66. Guerrini R et al. Nonsyndromic mental retardation and cryptogenic epilepsy in women with doublecortin gene mutations. Ann Neurol. 2003;54(1):30–7.
67. Romaniello R et al. Brain malformations and mutations in α- and β-tubulin genes: a review of the literature and description of two new cases. Dev Med Child Neurol. 2014;56(4):354–60.
68. Dobyns WB. The clinical patterns and molecular genetics of lissencephaly and subcortical band heterotopia. Epilepsia. 2010;51 Suppl 1:5–9.
69. Matalon D et al. Confirming an expanded spectrum of SCN2A mutations: a case series. Epileptic Disord. 2014;16(1):13–8.
70. Allen NM et al. The variable phenotypes of KCNQ-related epilepsy. Epilepsia. 2014;55(9):e99–e105.
71. Bahi-Buisson N et al. Recurrent mutations in the CDKL5 gene: genotype-phenotype relationships. Am J Med Genet A. 2012;158A(7):1612–9.
72. Mignot C et al. STXBP1-related encephalopathy presenting as infantile spasms and generalized tremor in three patients. Epilepsia. 2011;52(10):1820–7.
73. Kortüm F et al. The core FOXG1 syndrome phenotype consists of postnatal microcephaly, severe mental retardation, absent language, dyskinesia, and corpus callosum hypogenesis. J Med Genet. 2011;48(6):396–406.
74. Sherr EH. The ARX story (epilepsy, mental retardation, autism, and cerebral malformations): one gene leads to many phenotypes. Curr Opin Pediatr. 2003;15(6):567–71.
75. Hartmann H et al. Agenesis of the corpus callosum, abnormal genitalia and intractable epilepsy due to a novel familial mutation in the Aristaless-related homeobox gene. Neuropediatrics. 2004;35(3):157–60.
76. Guerrini R et al. Expansion of the first PolyA tract of ARX causes infantile spasms and status dystonicus. Neurology. 2007;69(5):427–33.
77. Saitsu H et al. Dominant-negative mutations in alpha-II spectrin cause West syndrome with severe cerebral hypomyelination, spastic quadriplegia, and developmental delay. Am J Hum Genet. 2010;86(6):881–91.
78. Kurian MA et al. Phospholipase C beta 1 deficiency is associated with early-onset epileptic encephalopathy. Brain. 2010;133(10):2964–70.
79. Ruggieri M et al. Neurofibromatosis type 1 and infantile spasms. Childs Nerv Syst. 2009;25(2):211–6.
80. Bahi-Buisson N et al. Spectrum of epilepsy in terminal 1p36 deletion syndrome. Epilepsia. 2008;49(3):509–15.
81. Saito Y et al. Polymicrogyria and infantile spasms in a patient with 1p36 deletion syndrome. Brain Dev. 2011;33(5):437–41.
82. Verrotti A et al. Electroclinical features and long-term outcome of cryptogenic epilepsy in children with Down syndrome. J Pediatr. 2013;163(6):1754–8.
83. Giordano L et al. Seizures and EEG patterns in Pallister-Killian syndrome: 13 new Italian patients. Eur J Paediatr Neurol. 2012;16(6):636–41.
84. Conant KD et al. A survey of seizures and current treatments in 15q duplication syndrome. Epilepsia. 2014;55(3):396–402.
85. Méneret A et al. PRRT2 mutations and paroxysmal disorders. Eur J Neurol. 2013;20(6):872–8.
86. Girard JM et al. Progressive myoclonus epilepsy. Handb Clin Neurol. 2013;113:1731–6.
87. Lalioti MD et al. Dodecamer repeat expansion in cystatin B gene in progressive myoclonus epilepsy. Nature. 1997;386(6627):847–51.
88. Berkovic SF et al. Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. Am J Hum Genet. 2008;82(3):673–84.
89. Corbett MA et al. A mutation in the Golgi Qb-SNARE gene GOSR2 causes progressive myoclonus epilepsy with early ataxia. Am J Hum Genet. 2011;88(5):657–63.
90. Trujillo-Tiebas MJ et al. Novel human pathological mutations. Gene symbol: EPM2A. Disease: Lafora progressive myoclonus epilepsy. Hum Genet. 2007;121(5):651.
91. Chan EM et al. Mutations in NHLRC1 cause progressive myoclonus epilepsy. Nat Genet. 2003;35(2):125–7.
92. Ferlazzo E, et al. Mild Lafora disease: Clinical, neurophysiologic, and genetic findings. Epilepsia, 2014.
93. Mink JW et al. Classification and natural history of the neuronal ceroid lipofuscinoses. J Child Neurol. 2013;28(9):1101–5.
94. Steinfeld R et al. Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genet. 2002;112(4):347–54.
95. Steinfeld R et al. Cathepsin D deficiency is associated with a human neurodegenerative disorder. Am J Hum Genet. 2006;78(6):988–98.
96. Muona M et al. A recurrent de novo mutation in KCNC1 causes progressive myoclonus epilepsy. Nat Genet, 2014.
97. Pearson TS et al. Phenotypic spectrum of glucose transporter type 1 deficiency syndrome (Glut1 DS). Curr Neurol Neurosci Rep. 2013;13(4):342.
98. Mefford HC et al. Genome-wide copy number variation in epilepsy: novel susceptibility loci in idiopathic generalized and focal epilepsies. PLoS Genet. 2010;6(5), e1000962.
99. Olson H et al. Copy number variation plays an important role in clinical epilepsy. Ann Neurol. 2014;75(6):943–58. This study analyzed 323 patients who have CNVs and epilepsy, and concluded that CNVs explained the epilepsy phenotype in at least 5% of the cases. It emphasizes the diagnostic yield of CMA in epilepsy.
100. Heinzen EL et al. Rare deletions at 16p13.11 predispose to a diverse spectrum of sporadic epilepsy syndromes. Am J Hum Genet. 2010;86(5):707–18.
101. Helbig I et al. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet. 2009;41(2):160–2.
102. de Kovel CG et al. Recurrent microdeletions at 15q11.2 and 16p13.11 predispose to idiopathic generalized epilepsies. Brain. 2010;133(Pt 1):23–32.
103. Mullen SA et al. Copy number variants are frequent in genetic generalized epilepsy with intellectual disability. Neurology. 2013;81(17):1507–14.
104. Lü JJ et al. T-type calcium channel gene-CACNA1H is a susceptibility gene to childhood absence epilepsy. Zhonghua Er Ke Za Zhi. 2005;43(2):133–6.
105. Escayg A et al. Coding and noncoding variation of the human calcium-channel beta4-subunit gene CACNB4 in patients with idiopathic generalized epilepsy and episodic ataxia. Am J Hum Genet. 2000;66(5):1531–9.
106. D’Agostino D et al. Mutations and polymorphisms of the CLCN2 gene in idiopathic epilepsy. Neurology. 2004;63(8):1500–2.
107. Chioza B et al. Association between the alpha(1a) calcium channel gene CACNA1A and idiopathic generalized epilepsy. Neurology. 2001;56(9):1245–6.
108. Bonanni P et al. Generalized epilepsy with febrile seizures plus (GEFS+): clinical spectrum in seven Italian families unrelated to SCN1A, SCN1B, and GABRG2 gene mutations. Epilepsia. 2004;45(2):149–58.
109. Díaz-Otero F et al. Autosomal dominant nocturnal frontal lobe epilepsy with a mutation in the CHRNB2 gene. Epilepsia. 2008;49(3):516–20.
110. Ottman R et al. Genetic testing in the epilepsies–report of the ILAE Genetics Commission. Epilepsia. 2010;51(4):655–70.
111. Heron SE et al. Missense mutations in the sodium-gated potassium channel gene KCNT1 cause severe autosomal dominant nocturnal frontal lobe epilepsy. Nat Genet. 2012;44(11):1188–90.
112. Fanciulli M et al. LGI1 microdeletion in autosomal dominant lateral temporal epilepsy. Neurology. 2012;78(17):1299–303.
113. Pizzuti A et al. Epilepsy with auditory features: a LGI1 gene mutation suggests a loss-of-function mechanism. Ann Neurol. 2003;53(3):396–9.
114. Lee JH et al. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet. 2012;44(8):941–5.
115. Scheffer IE et al. Mutations in mammalian target of rapamycin regulator DEPDC5 cause focal epilepsy with brain malformations. Ann Neurol. 2014;75(5):782–7.
116. Dibbens LM et al. Mutations in DEPDC5 cause familial focal epilepsy with variable foci. Nat Genet. 2013;45(5):546–51. This study was fundamental in identifying DEPDC5 as a not only a cause, but the most common known cause of familial focal epilepsy, thus substantially improving our understanding of the pathophysiology of epilepsy but also shedding light on treatment strategies and prognosis.
117. Ishida S et al. Mutations of DEPDC5 cause autosomal dominant focal epilepsies. Nat Genet. 2013;45(5):552–5.
118. Lal D et al. DEPDC5 mutations in genetic focal epilepsies of childhood. Ann Neurol. 2014;75(5):788–92.
119. Picard F et al. DEPDC5 mutations in families presenting as autosomal dominant nocturnal frontal lobe epilepsy. Neurology. 2014;82(23):2101–6.
120. D’Gama AM et al. mTOR pathway mutations cause hemimegalencephaly and focal cortical dysplasia. Ann Neurol, 2015.
121. Carvill GL et al. GRIN2A mutations cause epilepsy-aphasia spectrum disorders. Nat Genet. 2013;45(9):1073–6.
122. Endele S et al. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nat Genet. 2010;42(11):1021–6.
123. Lemke JR et al. Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes. Nat Genet. 2013;45(9):1067–72.
124. Lesca G et al. GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet. 2013;45(9):1061–6.
125. Barba C et al. Co-occurring malformations of cortical development and SCN1A gene mutations. Epilepsia. 2014;55(7):1009–19.
126. Auerbach DS et al. Altered cardiac electrophysiology and SUDEP in a model of Dravet syndrome. PLoS One. 2013;8(10), e77843.
127. Delogu AB et al. Electrical and autonomic cardiac function in patients with Dravet syndrome. Epilepsia. 2011;52 Suppl 2:55–8.
128. Kalume F et al. Sudden unexpected death in a mouse model of Dravet syndrome. J Clin Invest. 2013;123(4):1798–808.
129. Le Gal F et al. A case of SUDEP in a patient with Dravet syndrome with SCN1A mutation. Epilepsia. 2010;51(9):1915–8.
130. Nabbout R. Can SCN1A mutations account for SUDEP?–Commentary on Hindocha et al. Epilepsia. 2008;49(2):367–8.
131. Veeramah KR et al. De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP. Am J Hum Genet. 2012;90(3):502–10.
132. Wagnon JL et al., Convulsive seizures and SUDEP in a mouse model of SCN8A epileptic encephalopathy. Hum Mol Genet. 2014.
133. Larsen J. et al. The phenotypic spectrum of SCN8A encephalopathy. Neurology, 2015.
134. Liebrechts-Akkerman G et al. PHOX2B polyalanine repeat length is associated with sudden infant death syndrome and unclassified sudden infant death in the Dutch population. Int J Legal Med. 2014;128(4):621–9.
135. Bagnall RD et al. Genetic analysis of PHOX2B in sudden unexpected death in epilepsy cases. Neurology. 2014;83(11):1018–21. In this study, genetic sequencing of PHOX2B, was performed on 68 patients who succombed to SUDEP, with no mutations found, showing that unlike sudden infant death syndrome, PHOX2B is unlikely to be associated with SUDEP.
136. Thibert RL et al. Neurologic manifestations of Angelman syndrome. Pediatr Neurol. 2013;48(4):271–9.
137. Pescosolido MF et al. Genetic and phenotypic diversity of NHE6 mutations in Christianson syndrome. Ann Neurol. 2014;76(4):581–93.
138. Tan WH et al. If not Angelman, what is it? A review of Angelman-like syndromes. Am J Med Genet A. 2014;164A(4):975–92.
139. Cordelli DM et al. Epilepsy in Mowat-Wilson syndrome: delineation of the electroclinical phenotype. Am J Med Genet A. 2013;161A(2):273–84.
140. de Pontual L et al. Mutational, functional, and expression studies of the TCF4 gene in Pitt-Hopkins syndrome. Hum Mutat. 2009;30(4):669–76.
141. Bao X et al. Using a large international sample to investigate epilepsy in Rett syndrome. Dev Med Child Neurol. 2013;55(6):553–8.
142. Neul JL et al. Rett syndrome: revised diagnostic criteria and nomenclature. Ann Neurol. 2010;68(6):944–50.
143. Nissenkorn A et al. Epilepsy in Rett syndrome–-the experience of a National Rett Center. Epilepsia. 2010;51(7):1252–8.
144. Pintaudi M et al. Epilepsy in Rett syndrome: clinical and genetic features. Epilepsy Behav. 2010;19(3):296–300.
145. Fehr S et al. The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy. Eur J Hum Genet. 2013;21(3):266–73.
146. Cardoza B et al. Epilepsy in Rett syndrome: association between phenotype and genotype, and implications for practice. Seizure. 2011;20(8):646–9.
147. Guerrini R, Parrini E. Epilepsy in Rett syndrome, and CDKL5- and FOXG1-gene-related encephalopathies. Epilepsia. 2012;53(12):2067–78.
148. Klein KM et al. A distinctive seizure type in patients with CDKL5 mutations: Hypermotor-tonic-spasms sequence. Neurology. 2011;76(16):1436–8.
149. Seltzer LE et al. Epilepsy and outcome in FOXG1-related disorders. Epilepsia. 2014;55(8):1292–300.
150. Striano P et al. West syndrome associated with 14q12 duplications harboring FOXG1. Neurology. 2011;76(18):1600–2.
151. Pearl PL, Gospe SM. Pyridoxal phosphate dependency, a newly recognized treatable catastrophic epileptic encephalopathy. J Inherit Metab Dis. 2007;30(1):2–4.
152. Giovannini S et al. Epilepsy in ring 14 syndrome: a clinical and EEG study of 22 patients. Epilepsia. 2013;54(12):2204–13.
153. Elens I et al. Ring chromosome 20 syndrome: electroclinical description of six patients and review of the literature. Epilepsy Behav. 2012;23(4):409–14.
154. Battaglia A. The inv dup (15) or idic (15) syndrome (Tetrasomy 15q). Orphanet J Rare Dis. 2008;3:30.
155. Scheffer IE. Epilepsy genetics revolutionizes clinical practice. Neuropediatrics. 2014;45(2):70–4.
156. Leuzzi V et al. Inborn errors of creatine metabolism and epilepsy. Epilepsia. 2013;54(2):217–27.
157. Mikati AG et al. Epileptic and electroencephalographic manifestations of guanidinoacetate-methyltransferase deficiency. Epileptic Disord. 2013;15(4):407–16.
158. Leen WG et al. Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain. 2010;133(Pt 3):655–70.
159. Mills PB et al. Genotypic and phenotypic spectrum of pyridoxine-dependent epilepsy (ALDH7A1 deficiency). Brain. 2010;133(Pt 7):2148–59.
160. Elterman RD et al. Randomized trial of vigabatrin in patients with infantile spasms. Neurology. 2001;57(8):1416–21.
161. Krueger DA et al. Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma. Neurology. 2013;80(6):574–80.
162. Guerrini R et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia. 1998;39(5):508–12.
163. Chiron C, Dulac O. The pharmacologic treatment of Dravet syndrome. Epilepsia. 2011;52 Suppl 2:72–5.
164. Touma M et al. Whole genome sequencing identifies SCN2A mutation in monozygotic twins with Ohtahara syndrome and unique neuropathologic findings. Epilepsia. 2013;54(5):e81–5.
165. Walleigh DJ, Legido A, Valencia I. Ring chromosome 20: a pediatric potassium channelopathy responsive to treatment with ezogabine. Pediatr Neurol. 2013;49(5):368–9.
166. Pierson TM et al. Mutation and early-onset epileptic encephalopathy: personalized therapy with memantine. Ann Clin Transl Neurol. 2014;1(3):190–8. This study provides a remarkable example of targeted therapy based on the knowledge of the genetic mutation causing epilepsy and its functional consequences.